http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022509609-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 |
| filingDate | 2019-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2022509609-A |
| titleOfInvention | Use of SHP2 inhibitors to treat insulin resistance |
| abstract | Despite the worldwide infestation, metabolic disorders, especially diabetes, are multifactorial in their causes, so there is still no efficient and specific treatment strategy. SHP2 is a ubiquitous tyrosine phosphatase that regulates major signaling pathways (eg, MAPK, PI3K) in response to many growth factors. We evaluate whether chronic inhibition of SHP2 can improve insulin sensitivity in animal models. Therefore, obese diabetic mice were treated by tube feeding (50 mg / kg / day). The present inventors note that the glucose tolerance of the treated animals was significantly improved as compared with the control, there was no change in body weight or body composition, and the fasting blood glucose level was lowered. Therefore, the present invention relates to the use of SHP2 inhibitors to treat insulin resistance. |
| priorityDate | 2018-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 168.